资讯

Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
BioSpace1 天
Novo’s Wegovy Inches Closer to Becoming First FDA-Approved GLP-1 Weight-Loss Pill
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
Wall Street Journal3 天
Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
Novo Nordisk NOVO.B2.62%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense ...
MPR20 小时
Milsaperidone Under Review for Bipolar I Disorder and Schizophrenia
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...
Managed Healthcare Executive3 天
FDA Sets Action Date for Oral Wegovy for Weight Loss
A decision is expected in the fourth quarter of 2025.
BusinessWorld on MSN2 天
FDA expects speedier drug permit process
THE new Food and Drug Administration (FDA) application procedures are expected to reduce the drug permit process by as much ...
Rheumatology Advisor3 小时
FDA Decision on Barth Syndrome Therapy Delayed Again
The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.
Novo Nordisk shares jump as FDA accepts oral Wegovy application
Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...